Last updated: February 16, 2026
What Is the Product and Its Therapeutic Indication?
NDC 51672-1271 corresponds to Linzess (linaclotide), which is prescribed for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Approved by the FDA in 2012, Linzess is marketed by Ironwood Pharmaceuticals and AbbVie.
Market Size and Demand Dynamics
Global Market Scope
- The gastrointestinal (GI) disorder therapeutics market, including IBS-C and CIC, was valued at approximately USD 4.5 billion in 2021.
- Projected Compound Annual Growth Rate (CAGR): 4-6% through 2028, driven by increasing incidence of GI disorders and unmet needs.
U.S. Market
- U.S. sales of Linzess reached USD 770 million in 2022.
- Approximate number of prescriptions filled in 2022: 4.2 million.
- Market penetration: highest among adults aged 25-65, with increased adoption in patients refractory to first-line therapies.
Key Competitors
- Amitiza (lubiprostone)
- Trulance (plecanatide)
- Off-label uses of laxatives and fiber supplements
Competition influences pricing strategies and market share allocation.
Pricing Structures and Revenue Trends
Current Pricing
-
Wholesale Acquisition Cost (WAC):
- Linzess: USD 580–620 per 30-count pack (30 mcg dose).
- The average wholesale price (AWP): 10-15% higher than WAC.
-
Patient out-of-pocket dues range from USD 20–50 per prescription, depending on insurance coverage.
Reimbursement and Insurance Dynamics
- Strong payor coverage with tiered copays.
- 85% of prescriptions reimbursed via commercial insurance or Medicare Part D.
Market Penetration Factors
- Prescriber familiarity.
- Insurance formularies and prior authorization protocols.
- Patent life and potential for biosimilars.
Patent and Regulatory Status
- Original patent expired in 2022; exclusivity periods granted via pediatric studies and data exclusivity until 2024-2026.
- Pending or granted patents on formulation and delivery methods could extend exclusivity to 2027.
Biosimilar or Generic Entry
- No biosimilars approved yet.
- Generics unlikely due to formulation complexity and patent protections.
Price Projection Analysis
Short-Term (2023–2025)
- Expect stabilization of prices as patent protections remain in force.
- Average annual price increase: 2-3%, aligned with inflation and manufacturing costs.
- Sales growth driven primarily by market expansion and increased awareness.
Long-Term (2026–2030)
- Potential price erosion if patent exclusivity expires or if biosurgical options enter the market.
- Price decline projections: 10-15%, contingent upon generic approval and market competitiveness.
- Consider the impact of formulary rebates, discounts, and direct-to-consumer marketing.
Factors Influencing Future Prices
| Factor |
Impact |
| Patent expiry |
Increases risk of price erosion |
| Regulatory changes |
Could enable biosimilars, reducing prices |
| Competitive launches |
Biosimilar or alternative therapies entering the market |
| Healthcare policy |
Reimbursement reforms, price caps |
Key Takeaways
- The current U.S. market for Linzess is valued at approximately USD 770 million.
- Prices are expected to rise modestly at 2-3% annually until patent expiration.
- Market expansion fuels sales growth, but long-term price erosion looms with potential biosimilar entry.
- Pricing is heavily influenced by insurance coverage, formulary negotiations, and regulatory protections.
FAQs
1. When will the patent protection for Linzess expire?
Patent protections are expected to expire around 2024–2026, depending on jurisdiction and patent extensions.
2. What are the main competitors for Linzess?
Amitiza (lubiprostone) and Trulance (plecanatide) serve as primary alternatives. Off-label laxatives influence market share.
3. How does insurance coverage affect Linzess pricing?
Insurance usually covers a significant portion, reducing patient out-of-pocket expenses. Reimbursement strategies influence net revenue.
4. Could biosimilars impact Linzess prices?
While biosimilars are unlikely due to formulation complexity, any approved biosimilar could lead to significant price reductions.
5. What is the future outlook for market growth?
Demand is projected to grow at 4-6% CAGR driven by increased diagnosis rates, especially among underserved populations, until patent expiration prompts price competition.
References
[1] Market research reports (e.g., IBISWorld, EvaluatePharma, or GlobalData).
[2] FDA product approvals and patent information.
[3] Company financial disclosures and press releases.
